Corrigendum: TEOA inhibits proliferation and induces DNA damage of diffuse large B-cell lymphoma cells through activation of the ROS-dependent p38 MAPK signaling pathway

• Xingxing Yu,
• Xingxing Yu,
• Xin Wang,
• Xu Wang,
• Xu Wang,
• Yi Zhou,
• Yi Zhou,
• Yanchun Li,
• Aiwei Wang,
• Tongtong Wang,
• Yihan An,
• Weidong Sun,
• Jing Du,
• Xiangmin Tong,
• Xiangmin Tong,
• Xiangmin Tong,
• Xiangmin Tong,
• Ying Wang

Affiliations

Xingxing Yu

Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Xingxing Yu

Department of Hematology, Fuyang Hospital of Anhui Medical University, Fuyang, China

Xin Wang

Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Xu Wang

School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China

Xu Wang

Department of Laboratory Medicine, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Yi Zhou

Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Yi Zhou

Wangjiangshan Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Yanchun Li

The Second Clinical Medical School of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China

Aiwei Wang

Department of Hematology, The First People’s Hospital of Fuyang, Hangzhou, China

Tongtong Wang

Wangjiangshan Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Yihan An

Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Weidong Sun

Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Jing Du

Department of Laboratory Medicine, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Xiangmin Tong

Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Xiangmin Tong

School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China

Xiangmin Tong

The Second Clinical Medical School of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China

Xiangmin Tong

Phase I Clinical Research Center, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Ying Wang

Phase I Clinical Research Center, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China